Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gen-Probe, MPI market cancer assays:

This article was originally published in Clinica

Executive Summary

San Diego, California-based Gen-Probe is to collaborate on a non-exclusive basis with Molecular Profiling Institute (MPI) to accelerate commercialisation of Gen-Probe's pipeline of cancer diagnostics. Under the terms of the agreement, of which the financial details were not disclosed, MPI will validate, commercialise and undertake market development activities for up to four Gen-Probe assays. The first of these will be the firm's investigational PCA3 test for prostate cancer. Gen-Probe, which acquired a minority stake in MPI as part of the agreement, will have a five-year right of first refusal should MPI seek a partner to develop non-tissue-based diagnostic products based on cancer and predictive medicine markers discovered or acquired by MPI.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT056953

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel